Back to results
US 2026/0055065 A1Published application
Pyridazinone compounds which modulate mutant proteins for treating respiratory diseases
AssigneeThe Hospital for Sick Children
InventorsChristine E Bear, Paul David William Eckford, Canhui Li, Mohabir Ramjeesingh, Ling-Jun Huan, Adrian Tanjala, Jia Xin Jiang, Daniel Vincent Paone, Jakob Busch-Petersen
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to pyridazinone compound of the Formula (I) for the treatment of respiratory diseases, such as, chronic obstructive pulmonary disease (COPD), cystic fibrosis, cancer, Long QT syndrome or Dravet syndrome, which arise as a result of mis-folded or mis-shaped proteins.
Claims22
A compound of the Formula (I)
- wherein
- R1 and R2 are independently or simultaneously H or (C1-C6)-alkyl;
- R3 and R4 are independently or simultaneously H or (C1-C6)-alkyl, or
- R3 and R4 are joined together, with the nitrogen atom to which they are attached, to form a (C5-C6)-heteroaryl or (C4-C6)-heterocycloalkyl, each of which is optionally substituted with halo, OH, (C1-C6)-alkyl, or halogenated-(C1-C6)-alkyl;
- Ring B is (C6-C10)-aryl or (C5-C10)-heteroaryl, each of which is optionally substituted with one or more of halo, OH, (C1-C6)-alkyl, halogenated-(C1-C6)-alkyl, (C3-C6)-cycloalkyl, or halogenated-(C3-C6)-cycloalkyl;
- W is (C1-C6)-alkyl or —(C0-C6)-alkylene-(C6-C10)-aryl, each of which is optionally substituted with one or more of halo, OH, CN, (C1-C6)-alkyl, halogenated-(C1-C6)-alkyl, (C1-C6)-alkoxy, (C3-C6)-cycloalkyl, or halogenated-(C3-C6)-cycloalkyl;
- or any pharmaceutically acceptable salt, stereoisomer or solvate thereof.
4 more elements
(canceled)
(canceled)
Dependencies are inferred from the claim text.